InMed is no longer an operating cannabinoid growth story; it is a proposed route into a privately financed migraine developer, with legacy drug assets left as contingent recovery opportunities. BayMedica, formerly the only revenue-producing business, has ceased operations. The remaining proprietary programs are not supported by a commitment to significant further internal development spending. That distinction changes what a common shareholder is buying: not an ingredient manufacturer recovering margins, but a closing-dependent minority interest in Mentari Therapeutics and potential proceeds from legacy assets. EDGAR identifies the issuer as InMed Pharmaceuticals Inc., Nasdaq ticker INM, incorporated in British Columbia. Its CIK is 1728328. This report covers FY2026, the fiscal year ended June thirty, and incorporates subsequent transaction disclosures available at the report date. The latest audited results, rather than a stale quarterly database, establish the starting point for the balance-sheet analysis. EDGAR identity.
The proposed financing is large relative to InMed's remaining resources, but it belongs to the future combined company rather than today's standalone balance sheet. Expected aggregate pre-closing financing reached approximately $490M after an additional placement was announced in July. Management expects that financing to support operations into 2029. Those are conditional funding and runway expectations, not a completed cash transfer to legacy shareholders. July transaction materials indicated approximately 1.15% ownership for pre-merger InMed holders following the transaction and financings, subject to the agreement's mechanics. The investment question is therefore whether a small interest in a better-funded migraine pipeline compensates for closing risk, changes in the capitalization denominator, and uncertain residual asset proceeds. A large headline financing cannot be treated as cash backing each existing common share. Source: Expanded financing.
The stance is cautious and event-driven rather than a conventional fundamental buy recommendation. Cash and short-term investments were approximately $2.23M at fiscal year-end. Continuing-operation cash consumption was about $8.64M over the fiscal year. A simple historical burn calculation leaves little standalone cushion, although the wind-down and transaction expenses make that calculation an imperfect forward forecast. The attractive element is access to a financed therapeutic strategy with a plausible unmet need; the weak element is that legacy ownership is small and contingent on completion. No current-price target is assigned because a verified September market quote and a finalized, fully diluted closing capitalization were not obtained. That limitation matters more here than attaching a precise valuation to the old cannabinoid revenue base. Audited cash flows.